1. Balch, C.M., Soong, S.J., Shaw, H.M., Milton, G.W.: An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In Cutaneous Melanoma, C.M. Balch, G.W. Milton, editors, Philadelphia, J.B. Lippincott Co., 1985, pp. 321–338
2. Balch, C.M., Soong, S.J., Shaw, H.M., Milton, G.W.: An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In Cutaneous Melanoma, C.M. Balch, G.W. Milton, editors, Philadelphia, J.B. Lippincott Co., 1985, pp. 338–346.
3. Hersey, P., Balch, C.M.: Current status and future prospects for adjuvant therapy of melanoma. Aust. N. Z. J. Surg.54:303, 1984
4. Cascinelli, N., Rumke, P., MacKie R., Morabito, A., Bufalino, R.: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol. Immunother.28:282, 1989
5. Balch, C.M., Smalley, R.V., Bartolucci, A.A., Burns, D., Presant, C.A., Durant, J.R.: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): Prognostic factors analysis and preliminary results of immunotherapy. Cancer49:1079, 1982